Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CG Therapeutics has entered into an agreement with the University of Washington to undertake a joint monoclonal antibody development program.
Subscribe to our email newsletter
CG Therapeutics is commercializing CG201, a proprietary vaccine that produces antibodies that neutralize hCG, a powerful hormone produced by tumor cell to speed their growth. The new joint program will develop human monoclonal antibodies against hCG that can be used with the CG201 vaccine to provide a comprehensive cancer treatment.
The program will be headed by University of Washington researchers Karl Eric and Ingegerd Hellstrom, who are renowned for their pioneering work in the application of monoclonal antibodies in the cancer field.
Tom Hopp, vice president of research for CG Therapeutics, said: “hCG is a promising oncology target and this research collaboration is poised to significantly enhance our efforts toward the development of effective hCG therapeutics.”